The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 17 of the 33 sources its claims cite were checked for support.
Abstract
Background: An imbalance in the immune system, stress response, and gut microbiota can contribute to the onset and progression of anxiety and depression. This pilot study aimed to explore the effect of Weizmannia coagulans BC99 on anxiety and depression through the gut microbiota–brain axis. Methods: A total of 79 participants with Hamilton Depression Rating Scale (HAMD-17) ≥ 8 or Hamilton Anxiety Rating Scale (HAMA-14) ≥ 7 were included and completed the study. The participants were randomly assigned to either the placebo group or the BC99 intervention group. The intervention lasted 8 weeks, with participants receiving either dextrin (3 g/day) or BC99 probiotics (3 g/day, 5 × 109 CFU) daily. Pre- and post-intervention comparisons were made on HAMD and HAMA scores, inflammatory cytokines, neurotransmitters, gut microbiota, and short-chain fatty acids. Results: Results showed that after 8 weeks, BC99 and placebo intervention were effective in reducing HAMD and HAMA scores, and HAMD and HAMA scores in BC99 group were reduced by 2.40 and 5.53 points compared the placebo group, and the response and remission rates were also higher than that of the placebo, but there was no significant difference. BC99 also could regulate the levels of inflammatory cytokines IL-17 and IL-10, and increase neurotransmitter levels of γ-GABA and NO. Moreover, compared with the placebo group, BC99 also enhanced the abundance of beneficial bacteria such as Faecalibactrium, Megamonas, Dialister, and Agathobacter, which were closely associated with clinical indicators of mental disorders, and increased the production of short-chain fatty acids. Conclusions: These preliminary findings suggested that BC99 might alleviate anxiety and depression symptoms by regulating the level of neurotransmitters or the change of microbiota, which needed further verification in subsequent animal or clinical experiments.
Overview
CoChat Summary
## TL;DR
This 8-week randomized, double-blind, placebo-controlled pilot trial tested Weizmannia coagulans BC99 in 79 adults with HAMD-17 ≥ 8 or HAMA-14 ≥ 7. BC99 showed improvements in anxiety/depression-related scores and several gut–brain axis biomarkers, but between-group differences in the main clinical outcomes were not statistically significant.
## Key findings
- 79 participants completed the study (82 randomized; 41 placebo, 41 BC99; 79 completed).
- HAMD-17 and HAMA-14 improved in both groups, and the BC99 group had larger reductions: HAMD decreased from 20.80 to 11.10 in BC99 vs 19.77 to 12.47 in placebo; HAMA also decreased more in BC99, but between-group differences were not significant.
- In the BC99 group, γ-GABA increased by 0.05 μmol/L vs placebo (p < 0.001), NO decreased (p < 0.001), and Cys-C decreased from 688.90 ng/mL to 533.52 ng/mL (p < 0.001).
- BC99 increased some gut microbiota and SCFA measures: propionic acid and isobutyric acid increased significantly (p < 0.05), and taxa including Faecalibacterium (+0.64-fold), Dialister (+4.78-fold), and Agathobacter (+1.30-fold) increased, while Escherichia-Shigella decreased (0.75-fold).
## Methods
- Design: Randomized, double-blind, placebo-controlled pilot study with 8 weeks of intervention; registered at ClinicalTrials.gov NCT06629441 and approved by an ethics committee.
- Sample/intervention: 82 eligible adults recruited in Luoyang, Henan, China; 79 completed. Participants were assigned 1:1 to BC99 (3 g/day; 5 × 10^9 CFU) or placebo (3 g/day dextrin).
- Main analysis: Baseline-to-week-8 changes in HAMD-17, HAMA-14, PSQI, GSES, cytokines (IL-17, IL-10), neurotransmitters (γ-GABA, NO, Cys-C, NPY), SCFAs, and 16S rDNA gut microbiota were analyzed mainly with baseline-adjusted ANCOVA; response/remission used logistic regression; microbiota used α/β diversity and compositional analyses.
## Limitations
- The paper states that the sample size was relatively small, which may have limited statistical power.
- The participants were relatively young and mainly from the same country, limiting generalizability.
- The authors state that the mechanism was not further analyzed in animal models.
- Evident from the text: although many biomarker and microbiota changes were reported, the primary between-group HAMD/HAMA differences were not statistically significant, so the clinical efficacy remains preliminary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
13 Valid · 1 Not valid · 12 Not checked · 102 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Such clinical relevance has also been observed in previous probiotic intervention studies, where probiotics showed beneficial but sometimes non-significant effects on depressive symptoms and anxiety [38,39,40].”
§ The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis > 4. Discussion
What the sources say
- Disputedcites [38] Romijn, 2017, A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression, Aust. N. Z. J. Psychiatry sourceExperimental — accuracy not yet measured
The Abstract Results (page unavailable) report no significant probiotic–placebo difference on any psychological outcome; 23% of probiotic recipients and 26% of placebo recipients met the depression-response threshold. The Discussion (page unavailable) says changes were remarkably similar and sometimes marginally greater with placebo, contrary to describing this trial as showing a beneficial, clinically relevant effect. The paper does report beneficial findings from other trials, but not from its own intervention. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [39] Goh, 2019, Effect of probiotics on depressive symptoms: A meta-analysis of human studies, Psychiatry Res. source
- Supportedcites [40] Slykerman, 2017, Effect of Lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: A randomised double-blind placebo-controlled trial, EBioMedicine source
The Introduction reports improvements in mood, stress, or anxiety in some prior probiotic trials, while the Discussion says not all studies found a significant positive effect. The Results also report significantly lower depression and anxiety scores in this paper’s probiotic group. Together, these passages support the cited sentence’s description of beneficial but sometimes non-significant findings. (LLM, conf=0.88)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Agathobacter enrichment might stabilize mood through SCFA synthesis and gut homeostasis [56].”
§ The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis > 4. Discussion
What the sources say
- Partly supportedcites [56] Clapp, 2017, Gut microbiota’s effect on mental health: The gut-brain axis, Clin. Pr. sourceExperimental — accuracy not yet measured
The Results and Discussion sections on the adult microbiome and on probiotics, inflammation, and the HPA axis discuss SCFA-related benefits and report mood improvements associated with changes to gut microbiota. They do not mention Agathobacter or establish that its enrichment stabilizes mood through SCFA synthesis and gut homeostasis. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Higher Firmicutes abundance has been associated with reduced depressive and anxiety symptoms through enhanced butyrate production, which modulates the gut-brain axis and alleviates neuroinflammation [49,50].”
§ The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis > 4. Discussion
What the sources say
- Partly supportedcites [49] Cao, Y., Cheng, Y., Pan, W., Diao, J., Sun, L., and Meng, M. (2025). Gut microbiota variations in depression and anxiety: A systematic review. BMC Psychiatry, 25. sourceExperimental — accuracy not yet measured
The Discussion links reduced abundance of particular bacteria in both anxiety and depression to lower butyrate production and weaker anti-inflammatory effects. It also reports lower Firmicutes in anxiety, but the Results say findings for Firmicutes in depression were contradictory. The review does not establish that higher Firmicutes abundance reduces symptoms through a butyrate-driven gut–brain and neuroinflammatory pathway. (LLM, conf=0.85)
- Partly supportedcites [50] Barroso, 2021, The aryl hydrocarbon receptor and the gut–brain axis, Cell. Mol. Immunol. sourceExperimental — accuracy not yet measured
The section on modulation of CNS inflammation reports that gut-microbial tryptophan metabolites activate AHR in astrocytes and limit CNS inflammation. It does not link higher Firmicutes abundance or butyrate production to reduced depression or anxiety symptoms; the mechanism it describes is different. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Figure 8A–E, after 8 weeks of BC99 intervention, total SCFAs, acetic acid, propionic acid, butyric acid, and isobutyric acid in the BC99 group all increase to varying degrees, among which the increased degree of propionic acid and isobutyric acid is statistically significant (p < 0.05).”
§ The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis > 3. Results > 3.7. SCFAs Level Analysis
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After 8 weeks of BC99 intervention, the concentration of Cys-C was significantly decreased compared with week 0, from 688.90 ng/mL to 533.52 ng/mL (p < 0.001).”
§ The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis > 3. Results > 3.5. Blood Hormone Levels and Neurotransmitter Indexes Analysis As shown in Figure 5A, compared with the first enrollment group, the concentration of γ-GABA in the placebo intervention group remained unchanged at 0.31 μmol/L. After 8 weeks of BC99 intervention, the level of γ-GABA increased significantly, with an increase by 0.05 μmol/L compared with the placebo group (p < 0.001). As a neurotransmitter, the level of NO was high in patients with major depression, and the level of NO could decrease after antidepressant treatment. As shown in Figure 5B, there is no significant difference in NO content after the placebo intervention, but the level of NO in the BC99 group is significantly lower than that in the placebo group after an 8-week intervention (p < 0.001). There was no significant difference in Cys-C content before and after intervention in the placebo groups (Figure 5C). After 8 weeks of BC99 intervention, the concentration of Cys-C was significantly decreased compared with week 0, from 688.90 ng/mL to 533.52 ng/mL (p < 0.001). Moreover, individuals with lower levels of NPY are more likely to experience negative emotional reactions, have difficulty coping with stress, and are more prone to anxiety and depression. There was no significant difference in the concentration of NPY between the placebo group and the BC99 group at week 8 (Figure 5D). To sum this up, after 8 weeks of BC99 intervention, γ-GABA level increased, and NO and Cys-C levels decreased, which might be related to the relief of anxiety and depression symptoms of the participants.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 128 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 28
- It may state two separate claims as one. 65
- The quote only partly states this claim. 1
Citations
Cites
The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.
(2015) · PubMed Central · Cited by 2,540
Gut–brain axis: How the microbiome influences anxiety and depression
Foster, J. A., & McVey Neufeld, K.-A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.01.005 · Cited by 2,460 · cited 1×
“Probiotics can improve mental health by mediating multiple pathways, such as regulating the neurotransmitters, metabolites, inflammatory cytokines, and the immune system [14,15].”
The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients?
Magne, F., Gotteland, M., Gauthier, L., Zazueta, A., Pesoa, S., Navarrete, P., & Balamurugan, R. (2020) · Nutrients · doi:10.3390/nu12051474 · Cited by 2,335
Altered fecal microbiota composition in patients with major depressive disorder
Jiang, H., Ling, Z., Zhang, Y., Mao, H., Ma, Z., Yin, Y., Wang, W., Tang, W., Tan, Z., Shi, J., et al. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.03.016 · Cited by 2,275 · cited 1×
“Elevated Faecalibacterium (e.g., F. prausnitzii ) could promote anti-inflammatory SCFAs, showing antidepressant and anxiolytic effects in animal models by modulating stress and neurotransmitters [54].”
The gut microbiota–brain axis in behaviour and brain disorders
Morais, L. H., Schreiber, H. L., & Mazmanian, S. K. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00460-0 · Cited by 2,149 · cited 1×
“As a result, the gut microbiota–brain axis has emerged as a promising target for interventions in mood disorders [10,11].”
The neuroactive potential of the human gut microbiota in quality of life and depression
Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., Schiweck, C., Kurilshikov, A., Joossens, M., Wijmenga, C., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0337-x · Cited by 1,963
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244 · cited 1×
“Recent studies have revealed a close relationship between gut microbiota and mood disorders, drawing increasing attention to the role of gut microbial communities in the onset and progression of these mood disorders [5,6].”
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193 · cited 1×
“Gut microbiota, as the “second brain” of the body, participates in various physiological processes such as digestion and absorption of nutrients, and immune regulation, as well as synthesis and metabolism of neurotransmitters [35].”
The gut microbiota in anxiety and depression—A systematic review
Simpson, C. A., Diaz-Arteche, C., Eliby, D., Schwartz, O. S., Simmons, J. G., & Cowan, C. S. M. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101943 · Cited by 912 · cited 1×
“Decreased Escherichia-Shigella might improve mood by reducing pro-inflammatory cytokines (e.g., IL-1 β ) and enhancing gut barrier integrity, mitigating systemic inflammation linked to depression via the gut-brain axis [52,53].”
Gut Microbiota’s Effect on Mental Health: The Gut-Brain Axis
Clapp, M., Aurora, N., Herrera, L., Bhatia, M., Wilen, E., & Wakefield, S. (2017) · Clinics and Practice · doi:10.4081/cp.2017.987 · Cited by 608 · cited 1×
“Agathobacter enrichment might stabilize mood through SCFA synthesis and gut homeostasis [56].”
Hays, K. E., Pfaffinger, J. M., & Ryznar, R. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2393270 · Cited by 453 · cited 1×
“SCFAs are a type of fatty acid with a carbon chain length of less than six carbon atoms, of which acetic acid, propionic acid, and butyric acid account for about 90% of the total [57].”
Slykerman, R. F., Hood, F., Wickens, K., Thompson, J. M. D., Barthow, C., Murphy, R., Kang, J., Rowden, J., Stone, P., Crane, J., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.013 · Cited by 422 · cited 1×
“Such clinical relevance has also been observed in previous probiotic intervention studies, where probiotics showed beneficial but sometimes non-significant effects on depressive symptoms and anxiety [38–40].”
Romijn, A. R., Rucklidge, J. J., Kuijer, R. G., & Frampton, C. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416686694 · Cited by 323 · cited 1×
“Such clinical relevance has also been observed in previous probiotic intervention studies, where probiotics showed beneficial but sometimes non-significant effects on depressive symptoms and anxiety [38–40].”
Depression's Unholy Trinity: Dysregulated Stress, Immunity, and the Microbiome
Cruz-Pereira, J. S., Rea, K., Nolan, Y. M., O'Leary, O. F., Dinan, T. G., & Cryan, J. F. (2020) · Annual Review of Psychology · doi:10.1146/annurev-psych-122216-011613 · Cited by 320
Extracellular vesicle–encapsulated IL-10 as novel nanotherapeutics against ischemic AKI
Tang, T.-T., Wang, B., Wu, M., Li, Z.-L., Feng, Y., Cao, J.-Y., Yin, D., Liu, H., Tang, R.-N., Crowley, S. D., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz0748 · Cited by 275 · cited 1×
“IL-10 is an anti-inflammatory cytokine, mainly produced by the central nervous system, such as the pituitary gland and hypothalamus, and has a variety of important functions in the human body, especially in immune and mood regulation [44].”
The gut microbiota–brain axis in neurological disorder
Ullah, H., Arbab, S., Tian, Y., Liu, C.-Q., Chen, Y., Qijie, L., Khan, M. I. U., Hassan, I. U., & Li, K. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1225875 · Cited by 255 · cited 1×
“Gut microbiota can communicate with the brain in two directions through various ways, such as nerve, endocrine, and immune ways, forming the so-called “gut microbiota-brain axis” [36].”
Hao, Z., Wang, W., Guo, R., & Liu, H. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.02.025 · Cited by 242 · cited 1×
“Decreased Escherichia-Shigella might improve mood by reducing pro-inflammatory cytokines (e.g., IL-1 β ) and enhancing gut barrier integrity, mitigating systemic inflammation linked to depression via the gut-brain axis [52,53].”
Placebo effect in the treatment of depression and anxiety
Kirsch, I. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00407 · Cited by 205 · cited 1×
“Kirsch et al. also studied the effects of antidepressants and placebo on depression, and found that there was no significant difference in outcomes between antidepressants and placebo, with 8.3 points and 10.1 points improvement, respectively, which was related to placebo response [37].”
InfluentialFuchs, T., Jefferson, S. J., Hooper, A., Yee, P.-H., Maguire, J., & Luscher, B. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.188 · Cited by 204 · cited 1×
“…role in the occurrence and development of anxiety and depression. γ -GABA, as an important inhibitory neurotransmitter in the brain, can reduce the excitability of neurons and maintain the balance between brain excitation and inhibition, thus producing sedative and anti-anxiety effects [45,46].”
Zhu, R., Fang, Y., Li, H., Liu, Y., Wei, J., Zhang, S., Wang, L., Fan, R., Wang, L., Li, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1158137 · Cited by 166
The aryl hydrocarbon receptor and the gut–brain axis
Barroso, A., Mahler, J. V., Fonseca-Castro, P. H., & Quintana, F. J. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00585-5 · Cited by 152 · cited 1×
“Higher Firmicutes abundance has been associated with reduced depressive and anxiety symptoms through enhanced butyrate production, which modulates the gut-brain axis and alleviates neuroinflammation [49,50].”
Ma, T., Jin, H., Kwok, L.-Y., Sun, Z., Liong, M.-T., & Zhang, H. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100294 · Cited by 152 · cited 1×
“At present, the total number of people with mental disorders worldwide is close to 1 billion, and anxiety and depression affect more than 300 million and 280 million people, respectively [33,34].”
Yu, Z., Li, D., & Sun, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114409 · Cited by 151 · cited 1×
“Escherichia-Shigella could induce intestinal inflammation and regulate immunity, which was positively correlated with the degree of inflammation in anxiety and depression, and was significantly reduced after BC99 intervention [51].”
Hao, W., Ma, Q., Wang, L., Yuan, N., Gan, H., He, L., Li, X., Huang, J., & Chen, J. (2024) · Microbiome · doi:10.1186/s40168-024-01756-6 · Cited by 143 · cited 1×
“For example, Hao et al. established a classic depression mouse model by the induction of mild pressure, and the mice showed depressive behavior and gut microbiota imbalance [8].”
Nikolova, V. L., Cleare, A. J., Young, A. H., & Stone, J. M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1817 · Cited by 140 · cited 2×
“The results found that after 8 weeks of probiotic intervention, the scores of HAMD-17, HAMA-14, and PSQI reduced, with high compliance and good tolerance, which provided preliminary evidence for the application of probiotics in the treatment of depression [16].”
The Microbiome-Gut-Brain Axis and Resilience to Developing Anxiety or Depression under Stress
Bear, T., Dalziel, J., Coad, J., Roy, N., Butts, C., & Gopal, P. (2021) · Microorganisms · doi:10.3390/microorganisms9040723 · Cited by 126 · cited 1×
“Despite advances in antidepressant therapies, their effectiveness remains suboptimal, with side effects including gastrointestinal issues, weight gain, sexual dysfunction, and other adverse reactions [3,4].”
Effect of probiotics on depressive symptoms: a meta-analysis of human studies
Goh, K. K., Liu, Y.-W., Kuo, P.-H., Chung, Y.-C. E., Lu, M.-L., & Chen, C.-H. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112568 · Cited by 123
Qian, X., Li, Q., Zhu, H., Chen, Y., Lin, G., Zhang, H., Chen, W., Wang, G., & Tian, P. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101798 · Cited by 120 · cited 1×
“Psychobiotics are generally living bacteria that can bring mental health benefits to the host by interacting with intestinal commensal bacteria after ingestion, and have the advantages of regulating gut microbiota, producing and transmitting neurotransmitters, etc. [18,19].”
Qiu, C., Gelaye, B., Zhong, Q.-Y., Enquobahrie, D. A., Frederick, I. O., & Williams, M. A. (2016) · Sleep and Breathing · doi:10.1007/s11325-016-1313-4 · Cited by 116 · cited 1×
“Generally speaking, a total score of less than or equal to 5 points indicated that the sleep quality of the participant was good, and a total score of more than 5 points indicated poor sleep quality [24].”
Merkouris, E., Mavroudi, T., Miliotas, D., Tsiptsios, D., Serdari, A., Christidi, F., Doskas, T. K., Mueller, C., & Tsamakis, K. (2024) · Microorganisms · doi:10.3390/microorganisms12020411 · Cited by 109 · cited 1×
“Probiotics, as an important mediator of gut microbiota regulation, have gradually become a research hotspot in recent years for their potential in mood disorders [13].”
Bifidobacterium: a probiotic for the prevention and treatment of depression
Li, J., Wang, J., Wang, M., Zheng, L., Cen, Q., Wang, F., Li, Z., Pang, R., & Zhang, A. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1174800 · Cited by 90 · cited 1×
“Psychobiotics are generally living bacteria that can bring mental health benefits to the host by interacting with intestinal commensal bacteria after ingestion, and have the advantages of regulating gut microbiota, producing and transmitting neurotransmitters, etc. [18,19].”
Ferrari, S., Mulè, S., Parini, F., Galla, R., Ruga, S., Rosso, G., Brovero, A., Molinari, C. G., & Uberti, F. (2024) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2024.03.011 · Cited by 81 · cited 1×
“Anxiety and depression are common mental disorders, accompanied by persistent depression and worry, excessive or inappropriate anxiety, sleep disruption, weight change, cognitive or motor dysfunction, and other symptoms [32].”
Gut microbiota variations in depression and anxiety: a systematic review
Cao, Y., Cheng, Y., Pan, W., Diao, J., Sun, L., & Meng, M. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06871-8 · Cited by 80
El Dib, R., Periyasamy, A. G., de Barros, J. L., França, C. G., Senefonte, F. L., Vesentini, G., Alves, M. G. O., Rodrigues, J. V. D. S., Gomaa, H., Gomes Júnior, J. R., et al. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.07.027 · Cited by 75
Rodríguez‐Landa, J. F., Germán-Ponciano, L. J., Puga-Olguín, A., & Olmos-Vázquez, O. J. (2022) · Molecules · doi:10.3390/molecules27113551 · Cited by 73 · cited 1×
“…role in the occurrence and development of anxiety and depression. γ -GABA, as an important inhibitory neurotransmitter in the brain, can reduce the excitability of neurons and maintain the balance between brain excitation and inhibition, thus producing sedative and anti-anxiety effects [45,46].”
Kang, J., Yang, L., Jia, T., Zhang, W., Wang, L., Zhao, Y., You, J., Deng, Y., Ge, Y., Liu, W., et al. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.09.041 · Cited by 73 · cited 1×
“Despite advances in antidepressant therapies, their effectiveness remains suboptimal, with side effects including gastrointestinal issues, weight gain, sexual dysfunction, and other adverse reactions [3,4].”
The role of gut microbiota and its metabolites short-chain fatty acids in food allergy
Chen, C., Liu, C., Zhang, K., & Xue, W. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.09.003 · Cited by 65 · cited 1×
“For example, Firmicutes could improve the function of the intestinal barrier and regulate neurotransmitter levels in the brain by producing SCFAs, and the BC99 group could effectively increase the abundance of Firmicutes [48].”
Alvarez-Mon, M. A., Gómez-Lahoz, A. M., Orozco, A., Lahera, G., Diaz, D., Ortega, M. A., Albillos, A., Quintero, J., Aubá, E., Monserrat, J., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030220 · Cited by 57 · cited 1×
“…through the following mechanisms, such as activating cells to secrete pro-inflammatory cytokines such as IL-6 and TNF-α , and destroying the blood–brain barrier and other pathways to affect the function of neurons and astrocytes, thus participating in the process of mental disorders [42,43].”
Bonsaksen, T., Grimholt, T. K., Skogstad, L., Lerdal, A., Ekeberg, Ø., Heir, T., & Schou‐Bredal, I. (2018) · BMC Public Health · doi:10.1186/s12889-018-5990-8 · Cited by 55 · cited 1×
“The higher the score, the higher the self-efficacy [25].”
Gut microbiome and Alzheimer’s disease: What we know and what remains to be explored
Kapoor, B., Biswas, P., Gulati, M., Rani, P., & Gupta, R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102570 · Cited by 46 · cited 2×
“Prevotella_9 is a genus of bacteria that plays an important role in gut microbiota and is associated with emotional, attentional, and sensory regions in the brain [30].”
Zhang, Y., Sun, Y., Liu, Y., Liu, J., Sun, J., Liu, X., Fan, B., Lü, C., & Wang, F. (2023) · Phytotherapy Research · doi:10.1002/ptr.7813 · Cited by 45 · cited 1×
“SCFAs play a variety of important roles in human health, including maintaining intestinal health, regulating the immune system, antibacterial and anti-tumor functions, and promoting energy metabolism [58,59].”
The Intervention of Prebiotics on Depression via the Gut–Brain Axis
He, Q., Si, C., Sun, Z., Chen, Y., & Zhang, X. (2022) · Molecules · doi:10.3390/molecules27123671 · Cited by 31 · cited 1×
“The onset of this disease is often accompanied by mental stress, behavioral changes, and, in severe cases, it can also increase the risk of complications such as cancer and suicide [2].”
Rizk, M., Bolton, L., Cathomas, F., He, H., Russo, S. J., Guttman‐Yassky, E., Mann, J. J., & Murrough, J. W. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23nr15243 · Cited by 30 · cited 1×
“…through the following mechanisms, such as activating cells to secrete pro-inflammatory cytokines such as IL-6 and TNF-α , and destroying the blood–brain barrier and other pathways to affect the function of neurons and astrocytes, thus participating in the process of mental disorders [42,43].”
Wang, G., Cao, L., Li, S., Zhang, M., Li, Y., Duan, J., Li, Y., Hu, Z., Wu, J., Ni, J., et al. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00582-w · Cited by 29 · cited 1×
“Once humans have mood disorders, the composition and function of gut microbiota can change, which is known as dysbiosis [7].”
Lan, Y., Wang, X., Yan, F., Zhang, W., Zhao, S., Song, Y., Wang, S., Zhu, Z., Wang, Y., & Liu, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c00296 · Cited by 28 · cited 1×
“SCFAs play a variety of important roles in human health, including maintaining intestinal health, regulating the immune system, antibacterial and anti-tumor functions, and promoting energy metabolism [58,59].”
Xie, S., Wang, C., Song, J., Zhang, Y., Wang, H., Chen, X., & Suo, H. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c03870 · Cited by 27 · cited 2×
“Probiotics can improve mental health by mediating multiple pathways, such as regulating the neurotransmitters, metabolites, inflammatory cytokines, and the immune system [14,15].”
Xiao, S., Yang, Z., Yan, H., Chen, G., Zhong, S., Chen, P., Zhong, H., Yang, H., Jia, Y., Yin, Z., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03012-9 · Cited by 23 · cited 2×
“In addition, the abundance of Agathobacter is usually related to intestinal barrier function and immunomodulatory capacity, and its abundance may be reduced in disease states [29].”
Zhao, L., Wang, Z., Tan, Y., Ma, J., Huang, W., Zhang, X., Jin, C., Zhang, T., Liu, W., & Yang, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115039 · Cited by 22
Ye, Z., Zhang, Y., Du, M., Lu, S., Zhao, Q., & Yang, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.830081 · Cited by 18 · cited 1×
“The detailed grade classification referred to the literature reported by Bonsaksen et al. [23].”
Weizmannia coagulans: an Ideal Probiotic for Gut Health
Zhang, S., Li, P., Lee, S., Wang, Y., Tan, C., & Shang, N. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250002 · Cited by 18
Zhai, S., Gao, Y., Jiang, Y., Li, Y., Fan, Q., Tie, S., Wu, Y., & Gu, S. (2024) · Journal of Food Science · doi:10.1111/1750-3841.17514 · Cited by 16 · cited 1×
“The detailed computer operation steps were carried out according to the method reported by Zhai et al. [26].”
Self-citationYuan, X., Chai, J., Xu, W., & Zhao, Y. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10326-z · Cited by 15 · cited 2×
“Propionic acid and isobutyric acid, produced by gut microbiota, can directly affect neuronal function after crossing the blood–brain barrier, such as the release of neurotransmitters, synaptic plasticity, and neurogenesis [31].”
Gasotransmitter‐Nanodonor for Spatial Regulation of Anxiety‐Like Behavior and Bone Metastasis
Zhang, J., Wang, P., Zhou, M., Wang, Y., Li, X., Guo, J., Zhu, X., Qing, X., Qian, J., Huang, X., et al. (2025) · Advanced Materials · doi:10.1002/adma.202416481 · Cited by 14 · cited 1×
“NO can participate in neural signal transmission and affect many biological functions, such as learning and memory, cognitive ability, and emotional interest [47].”
Sun, Q., Fan, J., Zhao, L., Qu, Z., Dong, Y., Wu, Y., & Gu, S. (2025) · Foods · doi:10.3390/foods14060989 · Cited by 14
Self-citationMurack, M., Kadamani, A. K., Guindon-Riopel, A., Traynor, O. H., Iqbal, U., Bronner, S., Messier, C., & Ismail, N. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107146 · Cited by 12 · cited 1×
“At present, the total number of people with mental disorders worldwide is close to 1 billion, and anxiety and depression affect more than 300 million and 280 million people, respectively [33,34].”
Zhang, Q., Yang, Y., Chen, Y., Ban, S., Gu, S., Li, F., Xue, M., Sun, J., Li, X., & Tie, S. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2024.141691 · Cited by 11 · cited 2×
“BC99 has the potential to optimize intestinal homeostasis, enhance immunity, regulate neurological function and important metabolites, and provide other multidimensional health benefits [12,21].”
Self-citationSun, Q., Fan, J., Zhao, L., Qu, Z., Dong, Y., Wu, Y., & Gu, S. (2025) · doi:10.20944/preprints202502.1825.v1 · Cited by 10
Self-citationGao, Y., Li, C., Li, J., Duan, M., Li, X., Zhao, L., Wu, Y., & Gu, S. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1498540 · Cited by 9 · cited 1×
“BC99 has the potential to optimize intestinal homeostasis, enhance immunity, regulate neurological function and important metabolites, and provide other multidimensional health benefits [12,21].”
Self-citationLan, Z., Yao, W., Xie, Y., Chen, W., Zhu, Y., Chen, J., Zhou, X., Huang, J., Wu, M., & Chen, J. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300603 · Cited by 9 · cited 1×
“Lan et al. also reported that oral troxerutin could reduce the levels of TNF-α and IL-6, and increase the level of IL-10 in serum, thus alleviating the symptoms of depression by improving peripheral inflammation [27].”
Unveiling the gut microbiota blueprint of schizophrenia: a multilevel omics approach
Qi, D., Liu, P., Wang, Y., Tai, X., & Ma, S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1452604 · Cited by 8 · cited 1×
“Recent studies have revealed a close relationship between gut microbiota and mood disorders, drawing increasing attention to the role of gut microbial communities in the onset and progression of these mood disorders [5,6].”
Cited by
Li, J., Liu, H., Wang, M., Dong, K., & Guo, R. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08097-8 · Cited by 6
“Tie, 2025 [52] found that post-intervention increases in acetate, propionate, and butyrate levels, along with reductions in depression scores, were more pronounced in the intervention group compared to controls.”
InfluentialWang, Y., Guo, J., Dong, Y., Zhu, J., Fang, S., Wu, Y., & Gu, S. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.02.032 · Cited by 4
Self-citationNeurocosmetics or Hype? Psychobiotic Potential of Strain-Specific Cosmeceuticals
Menni, A.-E., Theodorou, H., Tzikos, G., Stavrou, G., Theodorou, I. M., Semertzidou, E., Venieri, J., Ioannidis, A., Shrewsbury, A. D., & Kotzampassi, K. E. (2026) · Nutrients · doi:10.3390/nu18050817 · Cited by 2
“On the other hand, another strain, the Unique IS-2, is known to alleviate anxiety-like behaviors by up-regulating hippocampal BDNF [48], and the BC99 strain by regulating the level of neurotransmitters and/or the change in gut microbiota [54].”
Kowalczyk, M., Aebisher, D., Szpara, J., Czech, S., Kowalczyk, E., Majsterek, I., Bartusik‐Aebisher, D., & Henrykowska, G. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114705
“Additional pilot studies in populations with depressive and/or anxiety symptoms have reported concurrent shifts in microbiota composition together with changes in SCFA-related parameters [62].”
Tang, E. E. X., Siripaopradit, Y., Thanakitcharu, J., Tang, E. E. S., & Chan, L. F. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106987
Metadata
- Authors
- Tie, S., Pan, Y., Pang, C., Saman, A., Dong, Y., Fang, S., Zhu, J., Wu, Y., & Gu, S.
- Affiliations
- Henan University of Science and Technology (CN)
- College of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471000, China
- Wecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd., Suzhou 215200, China
- Corresponding author
- Wu, Ying
- Gu, Shaobin
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-09-28
- Volume
- 17
- Issue
- 19
- Pages
- 3087
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12525987
- OpenAlex
- W4414623064
- Cited by
- 11
- References
- 58
- Citations by year
- 2026: 11
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Major Science and Technology Special Projects in Henan Province (231100310200)
- Key R&D Projects in Henan Province (241111314200, 221111111400)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- probiotics, anxiety, depression, gut-brain axis, inflammatory cytokines, IL-17, IL-10, GABA, nitric oxide, short-chain fatty acids, Megamonas, Dialister, Agathobacter, neurotransmitters
- MeSH terms
- Eubacteriales, Gastrointestinal Microbiome, Adult, Anxiety, Brain, Depression, Fatty Acids, Volatile, Female, Humans, Male, Middle Aged, Pilot Projects, Cytokines, Treatment Outcome, Probiotics, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.